Core Laboratories/$CLB
1D1W1MYTD1Y5YMAX
Capital at risk
About Core Laboratories
Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.
- Ticker
- $CLB
- Sector
- Energy
- Primary listing
- NYSE
- Employees
- 3,300
- Headquarters
- Houston, United States
- Website
- www.corelab.com
CLB Metrics
BasicAdvanced
$525M
21.99
$0.52
1.06
$0.04
0.35%
Price and volume
Market cap
$525M
Beta
1.06
52-week high
$20.36
52-week low
$9.79
Average daily volume
469K
Dividend rate
$0.04
Financial strength
Current ratio
2.121
Quick ratio
1.302
Long term debt to equity
0.549
Total debt to equity
0.592
Dividend payout ratio (TTM)
7.60%
Interest coverage (TTM)
3.85%
Profitability
EBITDA (TTM)
57.902
Gross margin (TTM)
19.52%
Net profit margin (TTM)
4.69%
Operating margin (TTM)
8.29%
Effective tax rate (TTM)
32.89%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
4.53%
Return on equity (TTM)
9.05%
Valuation
Price to earnings (TTM)
21.992
Price to revenue (TTM)
1.017
Price to book
1.93
Price to tangible book (TTM)
3.28
Price to free cash flow (TTM)
49.242
Free cash flow yield (TTM)
2.03%
Free cash flow per share (TTM)
0.233
Dividend yield (TTM)
0.35%
Forward dividend yield
0.35%
Growth
Revenue change (TTM)
0.35%
Earnings per share change (TTM)
-16.07%
3-year revenue growth (CAGR)
0.61%
10-year revenue growth (CAGR)
-2.69%
3-year earnings per share growth (CAGR)
-14.86%
10-year earnings per share growth (CAGR)
-12.07%
10-year dividend per share growth (CAGR)
-33.02%
What the Analysts think about CLB
Analyst ratings (Buy, Hold, Sell) for Core Laboratories stock.
Analyst projections of the future price of Core Laboratories stock.
Bulls say / Bears say
Management issued third quarter 2026 revenue guidance of $128.5 million to $135.5 million, with a midpoint of $132 million, signaling confidence in sequential growth. (Investing.com)
Operating income ex-items in Q2 2026 jumped 42% sequentially to $9.4 million, demonstrating improved operational leverage and cost control. (SEC)
The company repurchased 214,712 shares for $2.7 million in Q2 2026 and maintained its quarterly dividend, underlining disciplined capital allocation and shareholder return commitment. (SEC)
Second quarter 2026 revenue fell 4% year-over-year to $124.6 million, indicating ongoing demand pressures in its core segments. (SEC)
Geopolitical tensions in the Middle East and expanded European sanctions on Russia disrupted client operations and suspended laboratory testing, weighing on core Reservoir Description services. (SEC)
The first quarter 2026 reported a GAAP loss of $0.02 per share and a 58% sequential drop in non-GAAP EPS ex-items, reflecting significant headwinds from severe weather and geopolitical instability. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
CLB Financial Performance
Revenues and expenses
CLB Earnings Performance
Company profitability
Upcoming events
No upcoming events
CLB News
AllArticlesVideos
Funds containing CLB
AllEURGBPUSD
Fund name | Fund size | $CLB weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.